Dysbiosis and Dementia: Unraveling The Microbial Imbalance in Alzheimer's Disease

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and hallmark pathological features such as amyloid-β plaque accumulation and tau protein hyperphosphorylation. While traditional research has primarily focused on central nervous system mechanisms, emerging evidence highlights the critical role of the microbiota–gut–brain axis (MGBA) in modulating the onset and progression of AD. The gut microbiota, a complex and dynamic community of microorganisms, interacts with the brain through neural, immune, endocrine, and metabolic pathways, thereby influencing brain function and homeostasis.

In healthy conditions, the gut microbiome maintains physiological balance by producing essential metabolites such as short-chain fatty acids (SCFAs), tryptophan derivatives, and bile acids, which regulate immune responses, neurotransmission, and blood–brain barrier (BBB) integrity. However, dysbiosis—an imbalance in gut microbial composition—has been strongly associated with AD. It is characterized by reduced microbial diversity, increased pro-inflammatory bacteria, and decreased beneficial metabolites. These alterations contribute to systemic inflammation, neuroinflammation, BBB disruption, oxidative stress, and mitochondrial dysfunction, all of which accelerate neurodegenerative processes.

Mechanistically, dysbiosis promotes activation of microglia and astrocytes, leading to chronic neuroinflammation and increased production of inflammatory cytokines. It also enhances amyloid-β deposition and tau pathology through inflammatory signaling, oxidative damage, and impaired clearance mechanisms. Furthermore, compromised BBB integrity allows harmful microbial products such as lipopolysaccharides (LPS) to enter the brain, exacerbating neuronal damage. Lifestyle and environmental factors—including diet, aging, stress, and medication use—further influence gut microbiota composition and contribute to disease progression.

Recent studies from both human and animal models provide strong evidence supporting the role of gut microbiota in AD pathogenesis and highlight potential microbial biomarkers for early detection. Therapeutic strategies targeting the gut microbiome, such as probiotics, prebiotics, fecal microbiota transplantation (FMT), dietary interventions (e.g., Mediterranean and ketogenic diets), and modulation of microbial metabolites, show promising results in reducing neuroinflammation and improving cognitive function.

Despite these advancements, challenges remain in establishing causality, standardizing methodologies, and translating preclinical findings into clinical practice. Future research integrating multi-omics approaches and artificial intelligence is essential for identifying precise mechanisms and developing personalized microbiome-based therapies.

In conclusion, gut microbiota dysbiosis plays a pivotal role in Alzheimer’s disease through interconnected pathways involving inflammation, metabolic dysfunction, and neuronal damage. Targeting the gut–brain axis offers a novel and promising direction for early diagnosis, prevention, and treatment of AD, potentially improving patient outcomes and quality of life.